Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig

Yin, D.P.; Sankary, H.N.; Williams, J.; Krieger, N.; Fathman, C.G.

Transplantation 62(11): 1537-1539

1996


ISSN/ISBN: 0041-1337
PMID: 8970603
Document Number: 455778
This study was designed to investigate the effectiveness of combined perioperative anti-CD4 and human (h)CTLA4Ig therapy in preventing allorejection of small bowel transplantation in high-responder Lewis rat recipients of ACI grafts. Anti-CD4 (5 mg/kg times 4 days) or hCTLA4Ig (0.5 mg/rat times 2 days) therapy alone delayed, but did not prevent, allograft rejection after small bowel transplantation of ACI into Lewis rats. All grafts were rejected in 18 and 10 days, respectively. However, a regimen of anti-CD4 (5 mg/kg times 4 days) combined with hCTLA4Ig (0.5 mg/rat times 2 days) allowed indefinite survival of ACI small bowel allografts. Second donor-matched heart grafts were permanently accepted, whereas third-party (Sprague-Dawley) heart allografts were rejected by the tolerant recipients. These data suggest that these two reagents produced a synergistic effect in preventing allorejection of small bowel transplantation.

Document emailed within 1 workday
Secure & encrypted payments